|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Intensified chemotherapy with ACVBP plus rituximab versus standard CHOP plus rituximab for the treatment of diffuse large B-cell lymphoma (LNH03-2B): an open-label randomised phase 3 trial显示文摘 | Christian Récher Bertrand Coiffier Corinne Haioun Thierry Jo Molina Christophe Fermé Olivier Casasnovas Catherine Thiéblemont André Bosly Guy Laurent Franck Morschhauser Hervé Ghesquières Fabrice Jardin Serge Bologna Christophe Fruchart Bernadette Corront | 2011 | 2011 (9806)2011，，9806： | 2 |
| 2 | Neutropenia in patients treated with rituximab显示文摘 | Voog E Morschhauser F Solal-Celigny P | 2003 | N Engl J Med2003，348，： | 1 |
| 3 | International Prognostic Index, Type of Transplant and Response to Rituximab Are Key Parameters to Tailor Treatment in Adults With CD20‐Positive B Cell PTLD: Clues From the PTLD‐1 Trial显示文摘 | R. U. Trappe S. Choquet D. Dierickx P. Mollee J. M. Zaucha M. H. Dreyling U. Dührsen C. Tarella O. Shpilberg M. Sender G. Salles F. Morschhauser A. Jaccard T. Lamy P. Reinke R. Neuhaus H. Lehmkuhl H. A. Horst M. Leith?user P. Schlattmann I. Anagnostopoulo | 2015 | American Journal of Transplantation2015，，4： | 1 |
| 4 | The transcription factor Mrr1p controls expression of the MDR1 efflux pump and mediates multidrug resistance in Candida albicans显示文摘 | Morschhauser J Barker K S Homayouni R | 2007 | PLoS Pathog2007，3，11： | 1 |
| 5 | Overexpression of the MDR1 gene is sufficient to confer increased resistance to toxic compounds in Candida albicans显示文摘 | HILLER D SANGLARD D MORSCHHAUSER J | 2006 | Antimicrob Agents Chemother2006，50，4： | 1 |
| 6 | Overexpression of the MDR1 gene is sufficient to confer increased resistance to toxic compounds in Candida albicans 显示文摘 | Hiller D Sanglard D Morschhauser J | 2006 | Antimicrob Agents Chemother2006，50，4： | 1 |
| 7 | Combination of ibrutinib with rituximab,cyclophosphamide,doxorubicin,vincristine,and prednisone(R-CHOP)for treatment-naive patients with CD20-positive B-cell non-Hodgkin lymphoma:a non-randomised,phase 1bstudy显示文摘 | Younes A Thieblemont C Morschhauser F | 2014 | Lancet Oncol2014，15，： | 1 |
| 8 | The genetic basis of fluconazole resistance development in Candida albicans显示文摘 | Morschhauser J | 2002 | Biochim Biophys Acta2002，1587，23： | 1 |
| 9 | Evaluation of minimal residual disease using reverse-transcription polymerase chain reaction in t(8;21) acute myeloid leukemia: a multicenter study of 51 patients显示文摘 | Morschhauser F Cayuela JM Martini S | 2000 | J Clin Oncol2000，18，4： | 1 |
| 10 | Overexpression of the MDR1 gene is sufficient to confer increased resistance to toxic compounds in Candida albicans显示文摘 | Hiller D Sanglard D Morschhauser J | 2006 | Antimicrob Agents Chemother2006，50，4： | 1 |
| 11 | Thegenetic basis of fluconazole re sistance development in Candida albicans显示文摘 | Morschhauser J | 2002 | Biochin Biophys Acta2002，1587，： | 1 |
| 12 | A phase Ⅱ study of enzastaurin, a protein kinase C beta inhibitor, in patients with relapsed or refractory mantle cell lymphomap 显示文摘 | Morschhauser F Seymour JF Kluin-Nelemans HC | 2008 | Ann Oncol2008，19，2： | 1 |
| 13 | Humanized anti-CD20 antibody, veltuzumab, in refractory/recurrent non-Hodgkin's lymphoma: phase 1/11 results显示文摘 | Morschhauser F Leonard JP Fayad L | 2009 | J Clin Oncol2009，27，20： | 1 |
| 14 | Obinutuzumab (GA101) monotherapy in relapsed/refractory diffuse large b-cell lymphoma or mantle-cell lymphoma: results from the phase II GAUGUIN study显示文摘 | MORSCHHAUSER FA CARTRON G THIEBLEMONT C | 2013 | J Clin Oncol2013，31，23： | 1 |
| 15 | Dur3 is the major urea transporter in Candida albica and is co-regulated with the urea amidolyase Durl, 2 显示文摘 | Navarathna DH Das A Morschhauser J | 2011 | Microbiology2011，57，1： | 1 |
| 16 | Obinutuzumab (GA101) in patients with relapsed/refractory indolent non-Hodgkin lymphoma: results from the phase Ⅱ GAUGUIN study显示文摘 | Salles GA Morschhauser F Solal-Céligny P | 2013 | J Clin Oncol2013，31，23： | 1 |
| 17 | The transcription factor Mrr1p controls expression of the MDR1 efflux pump and mediates mulfidrug resistance in Candids albicans显示文摘 | Morschhauser J Barker KS Liu TT | 2007 | PLoS Pethog2007，3，11： | 1 |
| 18 | Phase Ⅱ study of gemcitabine dexamethasone with or without cisplatin in relapsed or refractory mantle cell lymphoma显示文摘 | Morschhauser F Depil S | | 0，，： | 1 |
| 19 | Evaluation of Minimal Residual Disease Using Reverse-Transcription Polymerase Chain Reaction in t(8; 21 ) Acute Myeloid Leukemia:A Multicenter Study of 51 Patients显示文摘 | Morschhauser F Cayuela J M Martini S | 2000 | Journal of Clinical Oncology2000，18，4： | 1 |
| 20 | Molecular aspects of fluconazole resistance development in Candida albicans 显示文摘 | FRANZ R RUHNKE M MORSCHHAUSER J | 1999 | J Mycoses1999，42，78： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员